There is a lot more to Geltex than RenaGel (cholesterol, weight loss, infectious disease program). This is why several companies and investment partnerships such as the Equitable Companies (21% ownership) own sizable positions in Geltex. In fact, an investment group from England whose name escapes me at the moment purchased about 400,000 shares at $27 in the offering last spring.
As far as RenaGel goes, you are incorrect in your assertions of the market potential. Firstly, as many as 50% of patients develop hypercalcemia from the use of phoslo and/or tums. Additionally, there are other treatment considerations to be taken into account such as the independent management of phosphate, calcium and PTH levels.
Lastly, RenaGel will help the patient by allowing a higher quality of life (dietary considerations), fewer blood tests, and less constipation.
Also, Lone Capital LLC bought over 800,000 shares this summer. Let's see, should I believe they know what they're doing or ADEL7? Hmmm. |
